Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Topical Dorzolamide Prevents Increases in Retinal Vascular Resistance Following Sympathetic Activation
Author Affiliations & Notes
  • Riley Filister
    The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Edward Linton
    The University of Iowa Department of Ophthalmology and Visual Sciences, Iowa City, Iowa, United States
    Center for the Prevention and Treatment of Blindness, Iowa City VA Medical Center, Iowa City, Iowa, United States
  • Randy H Kardon
    The University of Iowa Department of Ophthalmology and Visual Sciences, Iowa City, Iowa, United States
    Center for the Prevention and Treatment of Blindness, Iowa City VA Medical Center, Iowa City, Iowa, United States
  • Footnotes
    Commercial Relationships   Riley Filister None; Edward Linton None; Randy Kardon None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1251. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Riley Filister, Edward Linton, Randy H Kardon; Topical Dorzolamide Prevents Increases in Retinal Vascular Resistance Following Sympathetic Activation. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1251.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Bursts of sympathetic activity, seen in pathologies like sleep apnea, may lead to increased local vascular resistance (VR) in ocular vasculature, potentially reducing ocular perfusion and increasing the risk of ischemic damage to the eye. We performed a prospective repeated-measures study to explore our hypotheses that a) sympathetic activity increases VR in vessels supplying the optic nerve head (ONH), choroid, and retina; and b) the commonly used ophthalmic medications brimonidine, an α2 agonist, and dorzolamide, a carbonic anhydrase inhibitor, could prevent increases in VR.

Methods : Ten healthy subjects (age 50-80) pretreated one eye with 1 drop of brimonidine TID for 3 days, then had their intraocular pressures measured with a Tono-Pen and measurements of peripheral arterial tone (PAT) amplitude, a measure inversely related to sympathetic activity, collected using WatchPAT 300 devices on both index fingers. Ocular blood flow (via laser speckle flowgraphy) and blood pressures were recorded at baseline and after submerging one foot in an ice-water bath (IWB) for 2 minutes. Patients repeated this protocol following a one-week washout and pretreating the same eye with 1 drop of dorzolamide (20 mg/mL) TID for 3 days. One-tailed paired t-tests were used for statistical analyses.

Results : Peripheral sympathetic activity was significantly increased following the IWB (p<0.0001). Increases in VR with the IWB were found in the ONH (p=0.0076), retina (p=0.0331), and choroid (p=0.0277) in untreated fellow eyes in dorzolamide trials. Pre-treatment with dorzolamide prevented an increase in VR in retinal vessels (p=0.3157) but significant VR increases still occurred in the ONH (p=0.0196) and choroid (p=0.0196). Pre-treatment with brimonidine did not prevent an increase in VR produced in the ONH (p=0.0195).

Conclusions : An increase in sympathetic activity was associated with increased VR in each vascular bed in dorzolamide trials. These effects were attenuated in the retinal vessels by topical dorzolamide. The lack of effect of dorzolamide on the choroid and ONH and lack of effect of brimonidine on all ocular vascular beds may be due to inadequate drug delivery to these vascular beds with topical administration. Future experiments in patients with unilateral Horner’s syndrome may further elucidate the role of sympathetic innervation on modulation of ocular perfusion.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×